PROCEPT BioRobotics Corporation (PRCT) exhibits 63.7% gross margins and -35.0% return on invested capital within Health Care (Medical/Dental Instruments), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 63.7% gross profitability converts into -33.7% operating margin and -35.0% ROIC, outpacing sector cost of capital.
ROIC: -35.0% // GM: 63.7%YoY revenue trajectory of +37.2% paired with -5.02% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +37.2% // FCF YLD: -5.02%Altman Z-Score of 3.98 and Piotroski F-Score of 4/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.98 // F-SCORE: 4/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $20.30 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Medical/Dental Instruments require continuous execution to defend 0.0% net margins.
NET MARGIN: 0.0% // D/E: 0.14x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for PRCT & activate live FRED threshold breach alerts.